ATE271613T1 - Modifizierte nodavirus-rns für die genverabreichung - Google Patents

Modifizierte nodavirus-rns für die genverabreichung

Info

Publication number
ATE271613T1
ATE271613T1 AT01915627T AT01915627T ATE271613T1 AT E271613 T1 ATE271613 T1 AT E271613T1 AT 01915627 T AT01915627 T AT 01915627T AT 01915627 T AT01915627 T AT 01915627T AT E271613 T1 ATE271613 T1 AT E271613T1
Authority
AT
Austria
Prior art keywords
modified
gene administration
rna1
nodavirus rna
orf
Prior art date
Application number
AT01915627T
Other languages
English (en)
Inventor
Giuliano Bensi
Alessio Zippo
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Application granted granted Critical
Publication of ATE271613T1 publication Critical patent/ATE271613T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/102—Plasmid DNA for yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Wrappers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01915627T 2000-03-24 2001-03-26 Modifizierte nodavirus-rns für die genverabreichung ATE271613T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007231.4A GB0007231D0 (en) 2000-03-24 2000-03-24 Modified rna for gene delivery
PCT/IB2001/000566 WO2001071017A2 (en) 2000-03-24 2001-03-26 Modified nodavirus rna for gene delivery

Publications (1)

Publication Number Publication Date
ATE271613T1 true ATE271613T1 (de) 2004-08-15

Family

ID=9888389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01915627T ATE271613T1 (de) 2000-03-24 2001-03-26 Modifizierte nodavirus-rns für die genverabreichung

Country Status (10)

Country Link
US (1) US7179457B2 (de)
EP (1) EP1268833B1 (de)
JP (2) JP4815091B2 (de)
AT (1) ATE271613T1 (de)
AU (1) AU2001242707A1 (de)
CA (2) CA2711685C (de)
DE (1) DE60104406T2 (de)
ES (1) ES2225502T3 (de)
GB (1) GB0007231D0 (de)
WO (1) WO2001071017A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114690C (zh) 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
US9644188B2 (en) * 2013-04-17 2017-05-09 ALN Rao Methods and molecules for suppression of RNA silencing
CN116350803B (zh) * 2023-05-19 2023-11-24 健通(济南)生物科技有限公司 一种以乳头瘤病毒样颗粒为载体的mRNA递药系统及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402898B (de) 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
FR2749323B1 (fr) 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
WO1998002548A2 (en) 1996-07-17 1998-01-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Infectious papillomavirus pseudoviral particles
CA2329509C (en) 1998-05-22 2009-10-06 Wisconsin Alumni Research Foundation Improved methods and materials for transformation
EP1105157B1 (de) * 1998-08-14 2006-11-02 Merck & Co., Inc. Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
AU5617200A (en) * 1999-06-14 2001-01-02 Uab Research Foundation, The Nodavirus-based dna expression vector and uses thereof

Also Published As

Publication number Publication date
WO2001071017A3 (en) 2002-04-04
WO2001071017A2 (en) 2001-09-27
US20030157130A1 (en) 2003-08-21
GB0007231D0 (en) 2000-05-17
CA2711685C (en) 2012-10-09
AU2001242707A1 (en) 2001-10-03
ES2225502T3 (es) 2005-03-16
DE60104406T2 (de) 2005-09-08
EP1268833B1 (de) 2004-07-21
CA2711685A1 (en) 2001-09-27
EP1268833A2 (de) 2003-01-02
CA2400667A1 (en) 2001-09-27
JP2011135897A (ja) 2011-07-14
CA2400667C (en) 2010-10-19
JP2003527863A (ja) 2003-09-24
DE60104406D1 (de) 2004-08-26
US7179457B2 (en) 2007-02-20
JP4815091B2 (ja) 2011-11-16

Similar Documents

Publication Publication Date Title
EP2601969A3 (de) Norovirus-impfstoff-formulierungen
WO2010019262A3 (en) Polyvalent vaccine
UA85536C2 (en) Viral antigens
ECSP066662A (es) Preparación farmacéutica que comprende un anticuerpo contra el receptor egf
WO2008014521A3 (en) Improved vaccines and methods for using the same
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
WO2010059689A3 (en) Rsv f vlps and methods of manufacture and use thereof
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
EP2261380A3 (de) Verfahren zur Verhinderung der Viruszellenfusion durch Verhinderung der Funktion des Fusionstartbereichs von RNA-Viren mit Klasse I membranfusogenen Hüllproteinen
UA93200C2 (ru) Лекарственная форма варденафила, которая быстро распадается bo рту
AP2003002734A0 (en) Purification of HBV antigens for use in vaccines.
ZA200710011B (en) A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein
MX2022014161A (es) Vacunas contra sars-cov-2.
WO2020035609A3 (en) Immunogenic compositions and uses thereof
CY1110662T1 (el) Απαλλαγμενοι απο πηκτωματα βλαστοι λιναριου και το παραπροϊον τους, καθως και η παραγωγη και η εφαρμογη τους
WO2006060257A3 (en) Bacterial packaging strains usefuel for generation and production of recombinant double-stranded rna nucleocapsids and uses thereof
ATE271613T1 (de) Modifizierte nodavirus-rns für die genverabreichung
MX2007013472A (es) Vacuna.
AU2001281931A1 (en) Improved microgels and films
WO2005001029A3 (en) Ancestral viruses and vaccines
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
WO2007112079A3 (en) Multivalent immunogen
WO2007016580A3 (en) Silencing rna molecules and their use in bone formation
WO2007025276A3 (en) Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies
WO2008063586A3 (en) Multicomponent vaccine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1268833

Country of ref document: EP

EEFA Change of the company name